Latest From Genta Inc.
Clinical trial failures and holds for drugs derived from nucleic acids from Alnylam and Ionis join those of Dicerna and Genta as the hit rate for these drugs continues to degrade. The real question is whether the failures have been due to a lack of efficacy or safety.
Partners AbbVie and Roche's Genentech scored an important win for their B-cell lymphoma-2 (BCL-2) inhibitor venetoclax in a Phase II clinical trial that met the study's primary endpoint in hard-to-treat chronic lymphocytic leukemia (CLL) patients, setting the stage for potential accelerated approval.
Loretta Itri told a longtime friend of the negative results of a Phase III study of Genasense in advanced melanoma before the news was public.
Despite putting up a fight, Genta has resorted to filing for Chapter 7 bankruptcy with the company's directors resigning with immediate effect.
- Antisense, Oligonucleotides
- Large Molecule
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Genta Inc.
- Senior Management
Raymond P Warrell Jr., MD, Chmn. & CEO
Gary Siegel, VP, Fin.
Loretta M Itri, MD, Pres., Pharmaceutical Dev. & CMO
- Contact Info
Phone: (908) 286-9800
200 Connell Dr.
Berkeley Heights, NJ 07922
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.